T1	Participants 151 185	320 multiple myeloma (MM) patients
T2	Participants 950 1061	defining poor prognosis patients (50% TRS: 16 months) characterised by pretreatment platelets of < or = 150,000
T3	Participants 1116 1150	Patients lacking both risk factors
